“Novo Nordisk Wipes Out $30 Billion In Market Value After Failed Heart Drug Trial”

What actually happened

Novo Nordisk's late-stage trial of ziltivekimab, a drug being tested to cut cardiovascular events like heart attack and stroke, failed to hit its efficacy goals. The company did not disclose the actual risk-reduction figure, and analysts said the drug would have needed to clear a 20% threshold to succeed. Shares fell sharply the same day, and the resulting market-cap loss is the headline's "$30 billion" figure.

Key facts

• Shares of Novo Nordisk dropped 9.3% to around $46.70 as of Friday morning, marking the stock's largest intraday loss since February and a 10.6% decline so far this year.
• Novo Nordisk reported Friday its ziltivekimab "did not achieve" goals to reduce major adverse cardiovascular events like a heart attack or stroke in a late-stage clinical trial, and it did not disclose how much the drug reduced risks.
• Jeffries analysts wrote in a note that ziltivekimab would have needed to show at least a 20% risk reduction, and the trial results were "strategically negative" as they effectively erased a growth opportunity for Novo Nordisk's business beyond its Ozempic and Wegovy market that could have been worth more than $10 billion annually.
• $30.7 billion. That's how much was cut from Novo Nordisk's market capitalization as of Friday's share price, lowering from $229.2 billion to $198.5 billion, marking a nearly 69% decline since hitting an all-time high of $635.7 billion in June 2024.

What to watch for

The headline's single-day framing buries the bigger story: this is a company already down nearly 69% from its 2024 peak, so watch whether follow-up coverage connects Friday's drop to that longer slide rather than treating it as an isolated shock. Also watch whether Novo Nordisk eventually discloses the actual risk-reduction number from the ziltivekimab trial, since withholding it now leaves room for the narrative to shift once the data are public.